Managing Sleep in Bipolar Disorder: An Overview of Pharmacological and Non-Pharmacological Interventions.

Bipolar DisordSep 1, 2026
Clinical ResearchPsychiatryOpen access

Valentina Baldini, Francesco Pasquino, Francesca Iannucci et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of pharmacological and non-pharmacological interventions for sleep disturbances in individuals with bipolar disorder (BD). Eleven studies were included, revealing that cognitive behavioral therapy for insomnia adapted for bipolar disorder (CBTI-BD) significantly improved sleep efficiency, latency, and total sleep time, while melatonin enhanced circadian alignment without mood destabilization.

Key findings

  • CBTI-BD improved sleep efficiency, latency, and total sleep time, along with reducing depressive symptoms.
  • Melatonin improved circadian alignment and sleep parameters without mood destabilization.
  • Antidepressants were associated with poorer sleep quality and increased impulsivity during euthymia.
  • Bright light therapy yielded mixed results regarding sleep improvement.

Why it matters

Sleep disturbances in bipolar disorder are linked to increased symptom severity and relapse risk. Effective management of sleep issues can enhance overall treatment outcomes and patient quality of life.

Source

PubMed · PMID 42687371Free full text on PubMed Central

Published in Bipolar Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.